Zentalis Pharmaceuticals, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
This filing consists entirely of boilerplate Sarbanes-Oxley certification exhibits (31.1, 31.2, 32.1, 32.2) signed by CEO Julie Eastland and CFO Vincent Vultaggio on August 6, 2026, for the Q2 2026 10-Q period ended June 30, 2026. The certifications confirm management's responsibility for disclosure controls and financial statement accuracy; no specific financial data, deals, transactions, or material changes are disclosed in these exhibits.
Why this rating
Routine SOX certification exhibits; boilerplate disclosures required by law; no operational or financial substance disclosed.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.